Berylliosis
An occupational lung disease caused by inhaling beryllium dust, leading to lung scarring and breathing difficulties.
Emergency Management: Acute respiratory failure requiring mechanical ventilation due to an acute exacerbation of pulmonary fibrosis or superimposed pneumonia.
Berylliosis, or Chronic Beryllium Disease (CBD), is a granulomatous interstitial lung disease caused by hypersensitivity to inhaled beryllium particles in genetically susceptible individuals.
Detailed Overview
Beryllium is a lightweight metal used in aerospace, nuclear, and electronics industries. Inhalation of its dust triggers a cell-mediated (Type IV) hypersensitivity reaction in the lungs of individuals with the HLA-DPB1 mutation. This immune response forms noncaseating granulomas, heavily resembling sarcoidosis, eventually leading to irreversible pulmonary fibrosis and restrictive lung disease.
Epidemiology & Demographics
Affects 2-5% of workers exposed to beryllium. Latency period from exposure to disease ranges from 3 months to 30 years.
Etiological Mechanism
Inhalation of beryllium dust, fumes, or alloys in the workplace triggering an immune response.
Primary Causes
Occupational exposure in aerospace manufacturing, nuclear weapons facilities, fluorescent lamp manufacturing (historically), and dental alloy manufacturing.
Inhaled beryllium acts as a hapten, binding to host proteins. In genetically susceptible individuals (HLA-DPB1), alveolar macrophages present the beryllium-protein complex to CD4+ T-helper cells. This triggers a Th1 cytokine cascade (IL-2, IFN-gamma, TNF-alpha), resulting in the formation of noncaseating granulomas in the pulmonary parenchyma and hilar lymph nodes. Chronic inflammation leads to fibroblast proliferation and interstitial fibrosis.
Diagnostic Criteria & Guidelines
Requires three components: 1. History of beryllium exposure. 2. Evidence of beryllium sensitization (positive Blood or BAL Beryllium Lymphocyte Proliferation Test [BeLPT]). 3. Evidence of granulomatous lung disease (noncaseating granulomas on lung biopsy or compatible imaging/PFTs).
Strict avoidance of further beryllium exposure. Oral Corticosteroids (e.g., Prednisone 20-40 mg/day for 3-6 months, then tapered) for symptomatic patients or those with declining lung function.
Second-Line & Adjunctive Therapy
For patients who cannot tolerate or fail steroids: Methotrexate (10-15 mg PO weekly) or Azathioprine (50-150 mg/day). Supplemental oxygen for resting or exertional hypoxemia (SpO2 < 88%).
Surgical & Procedural Management
Lung transplantation is the only definitive treatment for advanced, end-stage fibrotic disease failing medical therapy.
Patient Counseling & Advice
Inform the patient that CBD is a chronic, potentially progressive disease. Even with complete cessation of exposure, the immune response can continue to drive inflammation and fibrosis.
Follow-Up & Monitoring Schedule
Follow up every 3-6 months with PFTs, diffusing capacity (DLCO), and symptom assessment to monitor for progression and titrate immunosuppressives.
Preventive Strategies
Primary prevention requires strict workplace engineering controls (ventilation, enclosing processes) and personal protective equipment (N95 or higher respirators) to keep airborne beryllium below OSHA permissible exposure limits.
Highly variable. Some patients remain stable for years, while others progress rapidly to end-stage fibrosis and death. Median survival after diagnosis can range from 10 to 20 years depending on severity at presentation.